In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
about
Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumoniaMycoplasmas and ureaplasmas as neonatal pathogens.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.Mycoplasma pneumoniae and its role as a human pathogen.Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.Ureaplasma infection-mediated release of matrix metalloproteinase-9 and PGP: a novel mechanism of preterm rupture of membranes and chorioamnionitis.Cethromycin: a promising new ketolide antibiotic for respiratory infections.Mycoplasma pneumonia: Clinical features and management.Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.Mycoplasma pneumoniae: susceptibility and resistance to antibiotics.Antibiotics in development targeting protein synthesis.Cethromycin: a new ketolide antibiotic.Mycoplasma pneumoniae: A Potentially Severe Infection.
P2860
Q30416493-740ECCFD-FC6C-44C5-92C4-6E2C5AD42F29Q34077056-62826A8E-97EB-44B3-9C33-80C8B5698746Q34097662-63B8D24C-0DC8-44FD-BD6F-D7D1C12BDB88Q34281970-99792460-A749-4D43-808E-68F8A80C592BQ34335695-7792E6F9-B94A-4B27-89D5-D7680EF9CA3AQ35920629-40204F61-8CA4-4AB8-9113-8940B4BEBA0CQ37190851-DA1F8976-37FE-4F4A-BD09-5D7B04FE910DQ37489476-83EEBA54-3DFD-4976-9D78-46E7BCB3395CQ37585935-009824B1-C404-442E-93B5-36B848CE2AA6Q37697782-9558DF4C-F40F-45BB-941F-1384CAE7BDD8Q37771257-28C44F18-A466-45F0-B582-B134876765BBQ37850895-CC452AE8-D3B8-4636-B41B-ACA38D166441Q37869911-158FF832-F68E-4F2F-8E58-115C579ECE50Q37970724-85A7BF2F-835A-4528-A809-E3A5258D831EQ38086821-858BADF0-C93C-48E9-BC45-2568A05F5ECEQ55314495-C8E5BF68-768D-40A0-A421-BEE0C2B2DBCF
P2860
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@ast
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@en
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@nl
type
label
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@ast
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@en
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@nl
prefLabel
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@ast
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@en
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@nl
P2093
P2860
P1476
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
@en
P2093
Donna M Crabb
Ken B Waites
Lynn B Duffy
P2860
P356
10.1128/AAC.47.1.39-42.2003
P407
P577
2003-01-01T00:00:00Z